Results 241 to 250 of about 25,876,318 (284)

SGLT-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Masked by Concurrent Pneumoperitoneum Following Spinal Surgery Under General Anesthesia: A Case Report. [PDF]

J Clin Med
Kim M, Bhan J, Lee DG, Chung HS.
europepmc   +1 more source

Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes. [PDF]

Endocrinol Diabetes Metab
Zimmer KB, Gessner A, Kannenkeril D, Bosch A, Ströbel A, Schmieder RE, Maas R.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis

Journal of Cellular Physiology, 2022
AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi, Mina Maleki, Fatemeh Nasimi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar   +5 more
openaire   +2 more sources

Sodium–glucose co-transporter-2 inhibitors

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee, Kieran F. Docherty, Pardeep S. Jhund   +2 more
openaire   +1 more source

Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney

Journal of Diabetes and its Complications, 2016
Diabetic ketoacidosis is a serious metabolic condition that may occur in patients with either Type 1 or Type 2 diabetes. The accumulation of ketoacids in the serum is a consequence of insulin deficiency and glucagon excess. Sodium Glucose Transporter 2 (SGLT2) inhibitors are novel therapeutic treatments for improving glucose homeostasis in patients ...
Biff F, Palmer, Deborah J, Clegg, Simeon I, Taylor, Matthew R, Weir   +3 more
openaire   +2 more sources

Sodium-glucose transporter 2 inhibitors

Reactions Weekly
  +7 more sources

Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential

Clinical Nephrology, 2017
Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou, Kyriakos, Trigkidis, Christos, Kazazis   +2 more
openaire   +2 more sources

Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure

The American Journal of Cardiology, 2019
Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus, due to upregulation of SGLT2 receptors, glucose reabsorption is further increased.
Raktim K. Ghosh, Gopal Chandra Ghosh, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Tauseef Akhtar, Prakash Deedwania, Carl J. Lavie, Gregg C. Fonarow, Ashish Aneja   +8 more
openaire   +5 more sources

Sodium-glucose transporter inhibitors 2 in acutely ill patients

Current Opinion in Clinical Nutrition & Metabolic Care
Purpose of review Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have rapidly become central to the management of heart failure and chronic kidney disease. Their widespread use now extends into the peri-acute and critical-care setting, raising questions about whether these agents should be continued or ...
Fernando G, Zampieri, Melanie, Meersch, Emily, See   +2 more
openaire   +2 more sources